EA202191489A1 - Способы лечения миелопролиферативных расстройств - Google Patents

Способы лечения миелопролиферативных расстройств

Info

Publication number
EA202191489A1
EA202191489A1 EA202191489A EA202191489A EA202191489A1 EA 202191489 A1 EA202191489 A1 EA 202191489A1 EA 202191489 A EA202191489 A EA 202191489A EA 202191489 A EA202191489 A EA 202191489A EA 202191489 A1 EA202191489 A1 EA 202191489A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
methods
myeloproliferative disorders
isoxazolo
azepin
Prior art date
Application number
EA202191489A
Other languages
English (en)
Russian (ru)
Inventor
Адриан Сендерович
Майкл Купер
Original Assignee
Констеллейшен Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Констеллейшен Фармасьютикалс, Инк. filed Critical Констеллейшен Фармасьютикалс, Инк.
Publication of EA202191489A1 publication Critical patent/EA202191489A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EA202191489A 2018-11-27 2018-11-27 Способы лечения миелопролиферативных расстройств EA202191489A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
EA202191489A1 true EA202191489A1 (ru) 2021-09-10

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191489A EA202191489A1 (ru) 2018-11-27 2018-11-27 Способы лечения миелопролиферативных расстройств

Country Status (8)

Country Link
JP (2) JP7453230B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250004357A (cg-RX-API-DMAC7.html)
AU (1) AU2018451360B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010134A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120973A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191489A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105279SA (cg-RX-API-DMAC7.html)
WO (1) WO2020112086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112939A1 (en) 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020112086A1 (en) * 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021320151A1 (en) * 2020-08-04 2023-02-23 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating thrombocythemia
CN122439254A (zh) 2024-01-18 2026-07-21 株式会社Lg新能源 电极组件、二次电池和电池单元

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型
WO2020112086A1 (en) * 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders

Also Published As

Publication number Publication date
WO2020112086A1 (en) 2020-06-04
JP7453230B2 (ja) 2024-03-19
CA3120973A1 (en) 2020-06-04
KR102738936B1 (ko) 2024-12-06
SG11202105279SA (en) 2021-06-29
AU2018451360B2 (en) 2022-05-26
KR20210095904A (ko) 2021-08-03
KR20250004357A (ko) 2025-01-07
JP2024063214A (ja) 2024-05-10
JP2022519425A (ja) 2022-03-24
BR112021010134A2 (pt) 2021-08-24
AU2018451360A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
PH12021551180A1 (en) Methods of treating myeloproliferative disorders
CY1121997T1 (el) Κρυσταλλικες μορφες του 2-((4s)-6-(4-χλωροφαινυλ)-1-μεθυλ-4η-βενζο[c]ισοξαζολo[4,5-ε]αζεπιν-4-υλ)ακεταμιδιου
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
EA201990226A1 (ru) Способы и композиции для лечения миелофиброза
DK3230298T3 (da) 3-substituerede 5-amino-6H-thiazolo[4,5-d]pyrimidin-2,7-dion forbindelser til behandling og forebyggelse af virusinfektion
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
DK3215511T3 (da) Substituerede pyrazolo(1,5-a)pyrimidiner og deres anvendelse i behandlingen af medicinske lidelser
KR20230104752A9 (ko) 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물및 의학적 장애의 치료에서의 그의 용도
WO2015195863A8 (en) Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
EP3452480A4 (en) SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
DK3509598T3 (da) Ny anvendelse af triazolo(4,5-d)pyrimidinderivater til forebyggelse og behandling af bakteriel infektion
MX2019015212A (es) Compuestos para el tratamiento del sarcoma.
EA202090180A1 (ru) Композиции nk1-антагониста и способы лечения депрессии
MY199237A (en) Methods of treating ocular conditions
IL287745A (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
LT3532064T (lt) Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
MX2019015280A (es) Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias.
EA201792123A1 (ru) Лечение боли
EA201992004A1 (ru) Способы предотвращения или лечения офтальмологических заболеваний
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
DK3846788T3 (da) Pde11-hæmmere til anvendelse i behandling af parkinsons sygdom
EA201991488A1 (ru) Модуляторы калиевых каналов
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора